[35] Monti, D.A., Zabrecky, G., Kremens, D., Liang, T., Wintering, N.A., Bazzan, A.J
ACS Omega 5:1184911872
Semaglutide improved Kansas City Cardiomyopathy Questionnaire (KCCQ) scores by 7 to 8 points more than placebo, produced 13% weight loss, improved six-minute walk distance by approximately 20 meters, and reduced C-reactive protein (a marker of inflammation) by about 40%
This blog will explore why fatigue can occur, how to manage it effectively, and what to expect as your body adjusts to the medication
The Future of Semaglutide and GLP-1 Agonists The success of semaglutide has shown that GLP-1 agonists can really change how we treat metabolic diseases, including cases with a body mass index associated with obesity